KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 125 filers reported holding KEROS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $1,286,081 | -83.1% | 30,119 | -81.0% | 0.22% | -86.9% |
Q4 2022 | $7,623,511 | -2.0% | 158,757 | -23.2% | 1.64% | +51.5% |
Q3 2022 | $7,781,000 | +314.1% | 206,819 | +204.2% | 1.08% | +437.3% |
Q2 2022 | $1,879,000 | -75.2% | 67,997 | -51.3% | 0.20% | -81.3% |
Q1 2022 | $7,590,000 | +8.4% | 139,581 | +16.6% | 1.07% | +39.4% |
Q4 2021 | $7,003,000 | – | 119,681 | – | 0.77% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
Atom Investors LP | 49,981 | $3,526,000 | 0.36% |